SMARCA4 and neoplasm: On one hand, several reports showed the promising antitumor activity of ICIs against this type of tumor [11, 12, 13, 14], on the other hand, others reported the dessert immune microenvironment of SMARCA4‐deficient tumors with limited efficacy to ICIs [15].